Inventor · disambiguated record
Hans Olov Sjogren
Also filed as: SJOEGREN HANS OLOV · SJOGREN HANS OLOV · SJÖGREN HANS OLOV
2 granted patents·9 pending applications·5 citations·filing 2001–2019
47Inventor score
Top patents by PatentIndex Score
11 records- 0173US6773702B2Use of combretastatin A4 and its prodrugs as an immune enhancing therapyOXIGENE INC·Filed 2001·Granted Aug 10, 2004·5 cites·13 claims
- 0249US2020078453A1Methods of treating a mammal suffering from or susceptible to an immune reaction to drug treatmentIDOGEN AB·Filed 2019·Application pending·0 cites
- 0344US9839674B2Methods of inducing indolamine 2,3—dioxygenase (IDO)IDOGEN AB·Filed 2014·Granted Dec 12, 2017·0 cites·11 claims
- 0444US2011300142A1Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplantsSALFORD LEIF G·Filed 2008·Application pending·0 cites
- 0536US2013309198A1Composition comprising at least to compounds which induces indolamine 2,3 - dioxygenase (ido), for the treatment of an autoimmune disorder or suffering from immune rejection of organsSALFORD LEIF·Filed 2011·Application pending·0 cites
- 0635US2018028621A1Methods of inducing indolamine 2,3 - dioxygenase (ido)IDOGEN AB·Filed 2017·Application pending·0 cites
- 0730US2017014499A1Novel treatment methodIDOGEN AB·Filed 2016·Application pending·0 cites
- 0829US2019201431A1Ex vivo methods of inducing ido expression in antigen presenting cells using a compound selected from the group consisting of azacytidine, and decitabineIDOGEN AB·Filed 2017·Application pending·0 cites
- 0929US2019192543A1Novel useIDOGEN AB·Filed 2017·Application pending·0 cites
- 1029US2021299069A1Psammaplin a for modulating ido expressionIDOGEN AB·Filed 2017·Application pending·0 cites
- 1127US2016068809A1Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplantsIDOGEN AB·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hans Olov Sjogren files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →